LifeLabs® EMPOWERING HEALTHIER CANADIANS FOR OVER 60 YEARS

Breast Cancer

# Data shows how leading oncologists treated early breast cancer (EBC) patients with molecular residual disease (MRD), potentially impacting the trajectory of the disease (ASCO 2024)

## Background:

- The presence of ctDNA has been strongly associated with recurrence yet the clinical impact of early ctDNA detection in terms of therapeutic intervention remains unclear[1,2]
- In this multi-institution (4 geographic US regions) retrospective real-world analysis, ctDNA detection in the adjuvant setting was investigated to determine the impact on patients with stage I-III early breast cancer (testing was conducted between 11/2020 - 01/2024)[3]




- 45% of patients with negative imaging were shown to have MRD which led to a change in therapy; 56% of these patients achieved ctDNA clearance
- A subset of patients who had a change in systemic therapy with subsequent ctDNA clearance was associated with better prognosis, compared to those patients without ctDNA clearance

ctDNA detection informed shared decision-making and impacted routine clinical care for **91% of Signatera™ positive patients with EBC**

# Real world clinical use of positive ctDNA testing in adjuvant surveillance of patients with early breast cancer

## Patient/provider shared decision-making regarding plan for adjuvant surveillance*




*Contributing considerations include stage, grade, tumor subtype, recurrence risk, treatment options, patient preference, and others. Shared decision-making should include discussion of potential benefits, risk, and clinical actionability associated with ctDNA testing.
**Preferred
***Some providers in this cohort elected to: change endocrine therapy (ie: tamoxifen to aromatase inhibitor + ovarian suppression), start treatment with adjuvant CDK4/inhibitor, starts treatment with adjuvant PARK inhibitor) for patients with BRCA mutations)

### Ordering Signatera™ for your breast cancer patients:

Can be run at any time point from diagnosis through survivorship, using either the core biopsy or surgical resection.

### Learn more about LifeLabs Cancer Testing

**Hereditary Cancer Panel:** Understand your patients' genetic risk. Includes full sequencing and analysis of 84 of the most common genes linked to hereditary cancers, including breast, ovarian, colorectal, and more.

**Tumor Markers:** Monitor cancer progression, assess treatment response, and detect recurrence with comprehensive testing across multiple cancer types.

Learn More:
**lifelabs.com/oncology**

References: 1. Coombes C et al. Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence. Clinical Cancer Research. 2019;25(14):4255-4263. 2. Shaw JA et al. Serial postoperative circulating tumor DNA assessment has strong prognostic value during long-term follow-up in patients with breast cancer. JCO Precis Oncol. 2024;8:e2300456. 3. Marla Lipsyc-Sharf et al. Impact of circulating tumor DNA (ctDNA) surveillance on clinical care for patients with stage I-III breast cancer: Findings from a multi-institutional study. ASCO Annual Meeting 2024

LifeLabs® EMPOWERING HEALTHIER CANADIANS FOR OVER 60 YEARS

AUTHORIZED DISTRIBUTOR

natera™ | Signatera™ Residual disease test (MRD)